Champions Oncology Inc.'s (CSBR) CEO Ronnie Morris on Q2 2022 Results - Earnings Call Transcript

Dec. 13, 2021 7:33 PM ETChampions Oncology, Inc. (CSBR)
SA Transcripts profile picture
SA Transcripts
133.8K Followers

Champions Oncology, Inc. (NASDAQ:CSBR) Q2 2022 Earnings Conference Call December 13, 2021 4:30 PM ET

Company Participants

Ronnie Morris - President and Chief Executive Officer

David Miller - Chief Financial Officer

Conference Call Participants

Matt Hewitt - Craig-Hallum

Operator

Good afternoon, ladies and gentlemen, and welcome to the Champions Oncology’s Second Quarter Fiscal Year 2022 Earnings Call. At this time, all participants are in a listen-only mode and the floor will be open for your questions and comments following the presentation. [Operator Instructions]

It is now my pleasure to turn the floor over to your host, Dr. Ronnie Morris. Sir, the floor is yours.

Ronnie Morris

Good afternoon. I am Ronnie Morris, CEO of Champions Oncology. Joining me today is David Miller, our Chief Financial Officer. Thank you for joining us for our quarterly earnings call.

Before I begin, I will remind you that we will be making forward-looking statements during today's call and that actual results could differ materially from what is described in those statements. Additional information and factors that could cause results to differ is available in our Forms 10-Q and Form 10-K. A reconciliation of the non-GAAP financial measures that may be discussed during the call to GAAP financial measures is available in the earnings release.

Overall, we had another good quarter with solid growth in our Services business as well as progress in our software and drug discovery efforts. Our Oncology Research Services business had record revenues, while our bookings remain robust. We both continue to expand our service offerings and expand our customer base paving the way for continued growth.

We continue to be encouraged by Lumin, our new software platform that was rolled out a little more than a year ago. We have been licensing this platform to our customers using a SaaS model, and our

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.